

In the Claims

Please replace the claims with the following amended claim set.

1. (Previously presented) An isolated polypeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:1 that complexes with a major histocompatibility complex molecule type HLA-A2, wherein the amino acid sequence of said isolated polypeptide is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49), or CLGLSYDGL (SEQ ID NO:57).
2. (Previously presented) An isolated polypeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:1, that elicits an immune response from human lymphocytes, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49), or CLGLSYDGL (SEQ ID NO:57).
3. (Canceled)
4. (Previously presented) An isolated nonapeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:1, wherein either the amino acid following the N-terminal amino acid is L and the C-terminal amino acid is L, V, or I, or the amino acid following the N-terminal amino acid is M and the C-terminal amino acid is I, other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57), or GLEGAQAPL (SEQ ID NO:50).
- 5.-8. (Canceled)
9. (Previously presented) An isolated nonapeptide having the amino acid sequence GLYDGMHL (SEQ ID NO:42).

10. (Previously presented) An isolated decapeptide having the amino acid sequence GLYDGMHLI (SEQ ID NO:44).

11.-41. (Canceled)

42. (Previously presented) The nonapeptide of claim 4, wherein the amino acid following the N-terminal amino acid is L.

43. (Previously presented) The nonapeptide of claim 4, wherein the C-terminal amino acid is L.

44.-50. (Canceled)

51. (Previously presented) A decapeptide comprising the nonapeptide of claim 4.

52. (Previously presented) The isolated polypeptide of claim 1, wherein the polypeptide elicits an immune response from human lymphocytes.

53. (Previously presented) The isolated polypeptide of claim 52, wherein the polypeptide elicits an immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2.

54. (Previously presented) The isolated polypeptide of claim 52, wherein the immune response is a cytolytic response from human T-lymphocytes.

55. (Previously presented) The isolated polypeptide of claim 1, wherein the major histocompatibility complex molecule type HLA-A2 is HLA-A2.1.

56. (Canceled)